Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- PhysicsWallah shares fall 15%; sell-off wipes out Rs 12,000 crore from m-cap in 3 days post listing
- Airport lounge access through cards getting tougher: Factors you must know to avoid last-minute shock
- Bessemer chases AI startup that could disrupt India’s IT Sector
- Bullish on India's consumption, investors flock to fund retail sector startups
